The Salah Foundation is proud to support the H. Lee Moffitt Cancer Center in advancing precision cancer care through innovative research and clinical application. This partnership reflects a shared commitment to improving treatment outcomes through science-driven, patient-centered solutions.
Through a strategic partnership with the Salah Foundation, H. Lee Moffitt Cancer Center & Research Institute has developed and launched the breakthrough Salah Targeted Expression Panel (STEP), an advanced molecular diagnostic tool designed to improve treatment decision-making for patients with lung cancer.
STEP analyzes gene expression patterns in cancer samples, allowing clinicians to better understand how an individual tumor behaves at the molecular level. This information helps physicians identify the most appropriate targeted therapies and connect patients to relevant clinical trials, advancing the practice of personalized cancer care.
Since its introduction in 2021, STEP has moved beyond research into real-world clinical use. The panel has been validated and integrated into patient care at Moffitt, with more than 1,000 patient samples tested to date. This implementation reflects a critical milestone: translating sophisticated genomic science into tools that directly inform treatment choices.
The collaboration between Moffitt and the Salah Foundation continues to support deeper insight into how targeted therapies perform across diverse patient populations. By enabling precision diagnostics at scale, this partnership contributes to improved treatment alignment, more efficient clinical trial matching, and a growing understanding of cancer biology.
This partnership perfectly exemplifies how philanthropic investment can accelerate the translation of advanced genomic research into clinical practice. By supporting tools like STEP, the Salah Foundation contributes to scalable, precision-based approaches that strengthen cancer care delivery, expand access to targeted therapies, and deepen clinical insight into treatment effectiveness across patient populations.